Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801

Behavioural Brain Research

Volumn 236, Issue 1, 2013, Pages 16-22

  Reneerkens, Olga A H ^a,b   Rutten, Kris ^a,b,d   Bollen, Eva ^a,b   Hage, Thorsten ^c   Blokland, Arjan ^a,b   Steinbusch, Harry W M ^a,b   Prickaerts, Jos ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b European Graduate School of Neuroscience   (Netherlands)

^c Biocrea   (Germany)

^d GRÜNENTHAL GMBH   (Germany)

Author keywords

BAY 60 7550; CAMP; CGMP; Memory; Object recognition; Phosphodiesterase; PQ 10

Indexed keywords

BAY 60 7550; ESTERASE INHIBITOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE TYPE 10; PQ 10; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; ENZYME INHIBITION; FEMALE; LEARNING; MALE; MENTAL PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; RAT; RECOGNITION; TASK PERFORMANCE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; IMIDAZOLES; MALE; MEMORY; MEMORY DISORDERS; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SCOPOLAMINE HYDROBROMIDE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRIAZINES;

EID: 84865984857     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.08.019     Document Type: Article

References (63)

1. Blokland A., Schreiber R., Prickaerts J. Improving memory: a role for phosphodiesterases. Current Pharmaceutical Design 2006, 12:2511-2523.
2. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berlin) 2009, 202:419-443.
3. Son H., Lu Y.F., Zhuo M., Arancio O., Kandel E.R., Hawkins R.D. The specific role of cGMP in hippocampal LTP. Learning and Memory 1998, 5:231-245.
4. Frey U., Huang Y.Y., Kandel E.R. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 1993, 260:1661-1664.
5. Bailey C.H., Bartsch D., Kandel E.R. Toward a molecular definition of long-term memory storage. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:13445-13452.
6. Chien W.L., Liang K.C., Teng C.M., Kuo S.C., Lee F.Y., Fu W.M. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Molecular Pharmacology 2003, 63:1322-1328.
7. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
8. Threlfell S., Sammut S., Menniti F.S., Schmidt C.J., West A.R. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. Journal of Pharmacology and Experimental Therapeutics 2009, 328:785-795.
9. Boess F.G., Hendrix M., van der Staay F.J., Erb C., Schreiber R., van Staveren W., et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004, 47:1081-1092.
10. Imanishi T., Sawa A., Ichimaru Y., Miyashiro M., Kato S., Yamamoto T., et al. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. European Journal of Pharmacology 1997, 321:273-278.
11. Bernabeu R., Schmitz P., Faillace M.P., Izquierdo I., Medina J.H. Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport 1996, 7:585-588.
12. Matsumoto Y., Unoki S., Aonuma H., Mizunami M. Critical role of nitric oxide-cGMP cascade in the formation of cAMP-dependent long-term memory. Learning and Memory 2006, 13:35-44.
13. Prickaerts J., de Vente J., Honig W., Steinbusch H.W., Blokland A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. European Journal of Pharmacology 2002, 436:83-87.
14. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neuroscience and Biobehavioral Reviews 2010, 34:1307-1350.
15. Rutten K., Prickaerts J., Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiology of Learning and Memory 2006, 85:132-138.
16. Schreiber R., Vivian J., Hedley L., Szczepanski K., Secchi R.L., Zuzow M., et al. Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. European Neuropsychopharmacology 2007, 17:277-288.
17. Akkerman S., Blokland A., Reneerkens O., van Goethem N.P., Bollen E., Gijselaers H.J., et al. Object recognition testing: methodological considerations on exploration and discrimination measures. Behavioural Brain Research 2012, 232:335-347.
18. Zhang H.T., Crissman A.M., Dorairaj N.R., Chandler L.J., O'Donnell J.M. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 2000, 23:198-204.
19. Egawa T., Mishima K., Matsumoto Y., Iwasaki K., Fujiwara M. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Japanese Journal of Pharmacology 1997, 75:275-281.
20. Ghelardini C., Galeotti N., Gualtieri F., Romanelli M.N., Bucherelli C., Baldi E., et al. DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer. Naunyn-Schmiedeberg's Archives of Pharmacology 2002, 365:419-426.
21. van Donkelaar E.L., Rutten K., Blokland A., Akkerman S., Steinbusch H.W., Prickaerts J. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. European Journal of Pharmacology 2008, 600:98-104.
22. van der Staay F.J., Rutten K., Erb C., Blokland A. Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behavioural Brain Research 2011, 220:215-229.
23. van der Staay F.J., Rutten K., Barfacker L., Devry J., Erb C., Heckroth H., et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008, 55:908-918.
24. Grauer S.M., Pulito V.L., Navarra R.L., Kelly M.P., Kelley C., Graf R., et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. Journal of Pharmacology and Experimental Therapeutics 2009, 331:574-590.
25. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., Harms J.F., et al. Preclinical characterization of selective PDE10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. Journal of Pharmacology and Experimental Therapeutics 2008, 325:681-690.
26. Zhang H.T., Huang Y., Suvarna N.U., Deng C., Crissman A.M., Hopper A.T., et al. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berlin) 2005, 179:613-619.
27. Alderton W., Karran E., Ward S. Current and future perspectives in psychiatric drug discovery. Drug News and Perspectives 2009, 22:360-364.
28. Siuciak J.A. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 2008, 22:983-993.
29. Klinkenberg I., Blokland A. A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment. Psychopharmacology (Berlin) 2011, 215:549-566.
30. Prickaerts J., Steinbusch H.W., Smits J.F., de Vente J. Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. European Journal of Pharmacology 1997, 337:125-136.
31. Ennaceur A., Neave N., Aggleton J.P. Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix. Experimental Brain Research 1997, 113:509-519.
32. Rutten K., Lieben C., Smits L., Blokland A. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berlin) 2007, 192:275-282.
33. Rutten K., Prickaerts J., Hendrix M., van der Staay F.J., Sik A., Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. European Journal of Pharmacology 2007, 558:107-112.
34. Prickaerts J., Sik A., van Staveren W.C., Koopmans G., Steinbusch H.W., van der Staay F.J., et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochemistry International 2004, 45:915-928.
35. Sik A., van Nieuwehuyzen P., Prickaerts J., Blokland A. Performance of different mouse strains in an object recognition task. Behavioural Brain Research 2003, 147:49-54.
36. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., Chambers L., et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006, 51:386-396.
37. Andine P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Martensson E., et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. Journal of Pharmacology and Experimental Therapy 1999, 290:1393-1408.
38. Brosnan-Watters G., Wozniak D.F., Nardi A., Olney J.W. Acute behavioral effects of MK-801 in the mouse. Pharmacology Biochemistry and Behavior 1996, 53:701-711.
39. Hitchcock S.A., Pennington L.D. Structure-brain exposure relationships. Journal of Medicinal Chemistry 2006, 49:7559-7583.
40. Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59:367-374.
41. Domek-Lopacinska K., Strosznajder J.B. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Research 2008, 1216:68-77.
42. Siuciak J.A., McCarthy S.A., Chapin D.S., Fujiwara R.A., James L.C., Williams R.D., et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006, 51:374-385.
43. Siuciak J.A., McCarthy S.A., Chapin D.S., Martin A.N., Harms J.F., Schmidt C.J. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background. Neuropharmacology 2008, 54:417-427.
44. Hebb A.L., Robertson H.A., Denovan-Wright E.M. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. European Neuropsychopharmacology 2008, 18:339-363.
45. Mumby D.G. Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats. Behavioural Brain Research 2001, 127:159-181.
46. Winters B.D., Bussey T.J. Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. Journal of Neuroscience 2005, 25:52-61.
47. Aggleton J.P., Brown M.W. Interleaving brain systems for episodic and recognition memory. Trends in Cognitive Science 2006, 10:455-463.
48. Wixted J.T., Squire L.R. The role of the human hippocampus in familiarity-based and recollection-based recognition memory. Behavioural Brain Research 2010, 215:197-208.
49. Eichenbaum H., Yonelinas A.P., Ranganath C. The medial temporal lobe and recognition memory. Annual Review of Neuroscience 2007, 30:123-152.
50. Melichercik A.M., Elliott K.S., Bianchi C., Ernst S.M., Winters B.D. Nicotinic receptor activation in perirhinal cortex and hippocampus enhances object memory in rats. Neuropharmacology 2012, 62:2096-2105.
51. Stephenson D.T., Coskran T.M., Wilhelms M.B., Adamowicz W.O., O'Donnell M.M., Muravnick K.B., et al. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. Journal of Histochemistry and Cytochemistry 2009, 57:933-949.
52. van Staveren W.C., Steinbusch H.W., Markerink-van Ittersum M., Behrends S., de Vente J. Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. European Journal of Neuroscience 2004, 19:2155-2168.
53. van Staveren W.C., Steinbusch H.W., Markerink-Van Ittersum M., Repaske D.R., Goy M.F., Kotera J., et al. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. Journal of Comparative Neurology 2003, 467:566-580.
54. van Staveren W.C., Markerink-van Ittersum M., Steinbusch H.W., de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Research 2001, 888:275-286.
55. Sadhu K., Hensley K., Florio V.A., Wolda S.L. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. Journal of Histochemistry and Cytochemistry 1999, 47:895-906.
56. Reyes-Irisarri E., Markerink-Van Ittersum M., Mengod G., de Vente J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. European Journal of Neuroscience 2007, 25:3332-3338.
57. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., Krull D.L., et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Research 2003, 985:113-126.
58. Coskran T.M., Morton D., Menniti F.S., Adamowicz W.O., Kleiman R.J., Ryan A.M., et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. Journal of Histochemistry and Cytochemistry 2006, 54:1205-1213.
59. Loughney K., Snyder P.B., Uher L., Rosman G.J., Ferguson K., Florio V.A. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. Gene 1999, 234:109-117.
60. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). Journal of Biological Chemistry 1999, 274:18438-18445.
61. Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:7071-7076.
62. Rodefer J.S., Murphy E.R., Baxter M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. European Journal of Neuroscience 2005, 21:1070-1076.
63. Rodefer J.S., Saland S.K., Eckrich S.J. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2011, 62:1182-1190.